About luspatercept
Erythroid maturation agent
Used for
- Treats anemia in adults with beta thalassemia requiring regular transfusions.
- Treats anemia in adults with lower-risk myelodysplastic syndromes, including some requiring transfusions.
Usual adult dose
Usually injected under the skin every 3 weeks; dose depends on condition, weight, and response.
Common side effects
- Tiredness, headache, dizziness, or muscle and joint pain
- Nausea, diarrhea, or cough
- High blood pressure
- Blood clots, especially in beta thalassemia
Important warnings
- Blood pressure can rise; monitoring is needed.
- Clot risk may increase, particularly with beta thalassemia.
- May cause harm to an unborn baby.
- Not a substitute for needed blood transfusions.
Pregnancy
May harm an unborn baby. Pregnancy should be avoided during treatment and for at least 3 months afterward.
Breastfeeding
It is unknown whether luspatercept passes into breast milk. Breastfeeding is not recommended during treatment and for 3 months after the final dose.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.